| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0161-5890(91)90074-T |
| P953 | full work available at URL | https://api.elsevier.com/content/article/PII:016158909190074T?httpAccept=text/plain |
| https://api.elsevier.com/content/article/PII:016158909190074T?httpAccept=text/xml | ||
| P698 | PubMed publication ID | 1850114 |
| P2093 | author name string | A. C. Allison | |
| N. E. Byars | |||
| P2860 | cites work | Reshaping human antibodies for therapy | Q28290936 |
| Muramyl dipeptide-induced adjuvant arthritis | Q33903272 | ||
| Prevention of simian acquired immune deficiency syndrome with a formalin-inactivated type D retrovirus vaccine. | Q33927302 | ||
| Anti-peptide antibodies detect steps in a protein conformational change: low-pH activation of the influenza virus hemagglutinin | Q36217109 | ||
| Necrotic inflammatory reaction induced by muramyl dipeptide in guinea pigs sensitized by tubercle bacilli | Q36350513 | ||
| Differential regulation of IgG1 and IgE synthesis by interleukin 4. | Q36354355 | ||
| Correlation between in vivo anti-Pseudomonas and anti-Candida activities and clearance of carbon by the reticuloendothelial system for various muramyl dipeptide analogs, using normal and immunosuppressed mice. | Q36433792 | ||
| Biological activity of a new synthetic muramyl peptide adjuvant devoid of pyrogenicity | Q36435211 | ||
| The adjuvant effect of microbial products on the immune response | Q37204643 | ||
| Development of a new therapeutic approach to B cell malignancy. The induction of immunity by the host against cell surface receptor on the tumor | Q38246919 | ||
| Structure and function of human and murine receptors for IgG. | Q39486261 | ||
| An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity | Q39752133 | ||
| HLA-B27, Klebsiella and Ankylosing Spondylitis: Biological and Chemical Studies | Q40106137 | ||
| A formalin-inactivated whole SIV vaccine confers protection in macaques | Q42188961 | ||
| Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity | Q42216648 | ||
| Protection from genital herpes simplex virus type 2 infection by vaccination with cloned type 1 glycoprotein D. | Q45838945 | ||
| Validation of a first-generation Epstein-Barr virus vaccine preparation suitable for human use. | Q45845005 | ||
| Enhancement of antibody responses to influenza B virus haemagglutinin by use of a new adjuvant formulation | Q45849395 | ||
| Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: serological responses and clinical reactions | Q45891068 | ||
| Phase I clinical trial of a World Health Organisation birth control vaccine | Q47589339 | ||
| Granuloma formation in normal guinea pigs injected intradermally with aluminum and zirconium compounds | Q53991545 | ||
| Immune interferon release when a cloned cytotoxic T-cell line meets its correct influenza-infected target cell | Q59064879 | ||
| HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals | Q69022796 | ||
| Influence of adjuvants on the quantity, affinity, isotype and epitope specificity of murine antibodies | Q69090852 | ||
| The adjuvant activity of nonionic block polymer surfactants. I. The role of hydrophile-lipophile balance | Q70877253 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunology | Q101929 |
| immunologic adjuvant | Q967453 | ||
| P304 | page(s) | 279-284 | |
| P577 | publication date | 1991-03-01 | |
| P1433 | published in | Molecular Immunology | Q6895954 |
| P1476 | title | Immunological adjuvants: desirable properties and side-effects | |
| Immunological adjuvants: Desirable properties and side-effects | |||
| P478 | volume | 28 |
| Q80325274 | A new vaccine adjuvant (BOS 2000) a potent enhancer mixed Th1/Th2 immune responses in mice immunized with HBsAg |
| Q40381324 | A novel vaccinological evaluation of intranasal vaccine and adjuvant safety for preclinical tests |
| Q81459566 | Adjuvant effect of water-soluble polysaccharide (PAP) from the mycelium of Polyporus albicans on the immune responses to ovalbumin in mice |
| Q36745550 | Adjuvant effects of saponins on animal immune responses |
| Q74763372 | Adjuvant regulation of cytokine profile and antibody isotype of immune responses to Mycoplasma agalactiae in mice |
| Q38179732 | CD4 T cell defects in the aged: causes, consequences and strategies to circumvent |
| Q73781384 | Collagen minipellet as a controlled release delivery system for tetanus and diphtheria toxoid |
| Q47558629 | Combining agent based-models and virtual screening techniques to predict the best citrus-derived vaccine adjuvants against human papilloma virus. |
| Q73532358 | Development of FIV-specific cytolytic T-lymphocyte responses in cats upon immunisation with FIV vaccines |
| Q41187648 | Different patterns of cytokine induction in cultures of respiratory syncytial (RS) virus-specific human TH cell lines following stimulation with RS virus and RS virus proteins |
| Q40375908 | Effect of adjuvants on immune response and protective immunity elicited by recombinant Hsp60 (GroEL) of Salmonella typhi against S. typhi infection |
| Q38550791 | Enhanced immunogenicity of microencapsulated tetanus toxoid with stabilizing agents |
| Q45754165 | Epitope polarity and adjuvants influence the fine specificity of the humoral response against Semliki Forest virus specific peptide vaccines |
| Q77608031 | Fully mobilizing host defense: building better vaccines |
| Q43666239 | Functional characteristics of antibodies induced by Arg-gingipain (HRgpA) and Lys-gingipain (Kgp) from Porphyromonas gingivalis |
| Q73193379 | Immune effector cells induced by complete Freund's adjuvant exert an inhibitory effect on antigen-specific type 2 T helper responses |
| Q45951870 | Immunologic responses and adverse reactions to Freund's-adjuvanted porcine zona pellucida immuno-contraceptives in domestic cats. |
| Q50634543 | Immunological adjuvant effect of Japanese ginseng saponins (JGS) on specific antibody and cellular response to ovalbumin and its haemolytic activities. |
| Q40792035 | Induction of a cytotoxic T-cell response to HIV-1 proteins with short synthetic peptides and human compatible adjuvants |
| Q40047371 | Influence of epitope polarity and adjuvants on the immunogenicity and efficacy of a synthetic peptide vaccine against Semliki Forest virus |
| Q43522758 | Influenza virus neutralizing antibodies and IgG isotype profiles after immunization of mice with influenza A subunit vaccine using various adjuvants |
| Q74664398 | Interaction of tumor and normal blood cells with ethylene oxide and propylene oxide block copolymers |
| Q91830598 | Interplay of oxidative stress and antioxidant bio markers in oil adjuvant Brucella melitensis vaccinated and challenged mice |
| Q37592383 | Novel adjuvants & delivery vehicles for vaccines development: a road ahead |
| Q35003701 | Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity |
| Q34806001 | Novel vaccine strategies |
| Q55380286 | Outer Membrane Vesicles: Current Status and Future Direction of These Novel Vaccine Adjuvants. |
| Q35044554 | Poly-D,L-lactide-co-poly(ethylene glycol) microspheres as potential vaccine delivery systems |
| Q39078061 | Protection against Schistosoma mansoni infection with a recombinant baculovirus-expressed subunit of calpain |
| Q73315957 | Red blood cells as delivery system for recombinant HSV-1 glycoprotein B: immunogenicity and protection in mice |
| Q61800975 | Sol-gel derived boehmite nanostructures is a versatile nanoplatform for biomedical applications |
| Q77626281 | Tetanus toxoid microspheres consisting of biodegradable poly(lactide-co-glycolide)- and ABA-triblock-copolymers: immune response in mice |
| Q34680503 | The development and use of vaccine adjuvants |
| Q38058650 | The use of propolis as vaccine's adjuvant |
| Q64917249 | Tocopherol Emulsions as Functional Autoantigen Delivery Vehicles Evoke Therapeutic Efficacy in Experimental Autoimmune Encephalomyelitis. |
| Q27485953 | Toxicological Safety Evaluation of DNA Plasmid Vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile Virus Is Similar Despite Differing Plasmid Backbones or Gene-Inserts |
| Q35556712 | Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12. |
| Q35372676 | Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. |
| Q34131456 | Unmet needs in modern vaccinology: adjuvants to improve the immune response |
| Q37098801 | Vaccine adjuvants - Current status and prospects on controlled release adjuvancity |
| Q36750711 | Vaccine adjuvants revisited |
| Q40949035 | Vaccine therapy for cancer |
Search more.